Sunitinib (SU) response in imatinib-resistant (IM-R) GIST correlates with <i>KIT</i> and <i>PDGFRA</i> mutation statusMichael C. Heinrich, G. D. Demetri, Robert G. Maki et al.|Journal of Clinical Oncology|2006Cited by 83
A phase I/II trial of the oral mTOR-inhibitor everolimus (E) and imatinib mesylate (IM) in patients (pts) with gastrointestinal stromal tumor (GIST) refractory to IM: Study updateA. van Oosterom, G. D. Demetri, Herlinde Dumez et al.|Journal of Clinical Oncology|2005Cited by 46
Mechanisms of sunitinib malate (SU) resistance in gastrointestinal stromal tumors (GISTs)Michael C. Heinrich, Jonathan A. Fletcher, Christopher L. Corless et al.|Journal of Clinical Oncology|2007Cited by 19
Clonal evolution of resistance to imatinib (IM) in patients (pts) with gastrointestinal stromal tumor (GIST): molecular and radiologic evaluation of new lesionsJayesh Desai, G. D. Demetri, Sharada Shankar et al.|Journal of Clinical Oncology|2004Cited by 8
Induction of TRAIL and XAF-1 and inhibition of p-Akt and c-Kit expression by interferons (IFNs) is associated with apoptosis in GIST cellsErnest C. Borden, Jonathan A. Fletcher, Barbara Jacobs et al.|Journal of Clinical Oncology|2004Cited by 1